Clinical trial · Observational
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
NCT07377747CI-TRIAL-00118024ReLaPSerecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Retroperitoneal Liposarcoma | Retroperitoneal Liposarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Surgery with preoperative radiotherapy
- description
- This includes patient who have had any chemotherapy.
- label
- Surgery without preoperative radiotherapy
- description
- This includes patients who had surgery alone, surgery with postoperative radiotherapy and/or any chemotherapy.
Primary outcomes (1)
- measure
- Abdominopelvic recurrence-free survival (ARFS). .
- timeFrame
- Up to 5 years.
- description
- Defined as the time from the date of treatment start (either surgery, chemo or RT) for 1st recurrent LPS to the date of radiological abdominopelvic relapse or death whichever occurred first. Liver metastases will be regarded as distant metastatic events. rather than abdominopelvic relapse
Secondary outcomes (14)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection) 2. No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease 3. Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only 4. Sarcoma not originating from bone or abdominal or gynecological viscera 5. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting) 6. WHO performance status 0-2 7. American Society of Anaesthesiologist (ASA) score 1-3 8. No prior RT for the retroperitoneal liposarcoma 9. Prior systemic therapy is allowed 10. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease) 11. Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment 12. Patient deemed able to comply with study requirements according to investigator evaluation 13. Signed, IRB-approved written informed consent Exclusion Criteria: 1. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team 2. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible 3. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease 4. Myxoid liposarcoma histology 5. Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.